Lipocine vs China SXT Pharmaceuticals
Lipocine is the larger business, with $2.0m of revenue in fiscal 2025 against $1.1m for China SXT Pharmaceuticals (1.7 times as much). China SXT Pharmaceuticals grew faster (-34.6% against -82.3%). Lipocine kept more of each dollar of sales as profit: a net margin of -487.1% against -545.2%. Lipocine carries less debt relative to equity (0.0% against 3.4%).
| Latest fiscal year | LipocineLPCN, 2025 | China SXT PharmaceuticalsSXTC, 2026 |
|---|---|---|
| Revenue | $2.0m | $1.1m |
| Revenue growth | -82.3% | -34.6% |
| Net income | −$9.6m | −$6.2m |
| Operating margin | -524.7% | -625.9% |
| Net margin | -487.1% | -545.2% |
| Return on equity | -54.3% | -27.5% |
| Free cash flow | −$9.8m | −$4.0m |
| Cash | $5.2m | $28.2m |
| Total debt | $0 | $999,565 |
| Debt to equity | 0.0% | 3.4% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 14 | — |
| Market value | $12.0m | $2.0m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | — |
| Insider trades, 12 months | 7 buys, 0 sales | 0 buys, 0 sales |